Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
about
Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme.Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus.Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.Innate Immune Memory Contributes to Host Defense against Recurrent Skin and Skin Structure Infections Caused by Methicillin-Resistant Staphylococcus aureus.β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4).In vitro activity of ceftaroline against clinical Staphylococcus aureus isolates collected during a national survey conducted in Belgian hospitals.Identification of non-PBP2a resistance mechanisms in Staphylococcus aureus after serial passage with ceftaroline: involvement of other PBPs.Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline.Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
P2860
Q35169054-26FAF6F8-C375-4C39-8E1B-64B31AABE1FAQ35822261-47340E15-F038-4F81-A23B-D1C88EC18859Q36138054-03122B8C-87B0-43BF-955A-FD4E409291DFQ37023150-9CC54047-B69A-458B-807C-7F42E1BC7CC4Q37597658-5EF2C1E5-534A-4D12-8054-99DBB49BC645Q37611964-3B94F12B-2739-43F5-872B-933A3D91E7EBQ38811605-A058A234-9C75-42AA-A1DC-1AFAE2AB5C3FQ38987098-05C75102-A694-4FD8-8933-C0DADA8DC008Q40266242-73D7D296-C3BB-439F-9056-9EB6523E43BDQ40538202-48CBA67B-D92C-4350-B503-BC8F78EFEA62Q40587085-B88EB469-5CEF-4414-8745-5BE610C0F808Q40867434-0310BFAD-9E97-475F-88E6-5496B3019E86Q50195416-24C5DD65-E280-4304-8EEF-7F8FFAA82944
P2860
Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Ceftaroline is active against ...... rmediate levels of resistance.
@en
Ceftaroline is active against ...... rmediate levels of resistance.
@nl
type
label
Ceftaroline is active against ...... rmediate levels of resistance.
@en
Ceftaroline is active against ...... rmediate levels of resistance.
@nl
prefLabel
Ceftaroline is active against ...... rmediate levels of resistance.
@en
Ceftaroline is active against ...... rmediate levels of resistance.
@nl
P2093
P2860
P356
P1476
Ceftaroline is active against ...... rmediate levels of resistance.
@en
P2093
Adriana E Rosato
Liliana I Paz
Regina Fernandez
Roberto R Rosato
P2860
P304
P356
10.1128/AAC.03019-14
P407
P577
2014-07-14T00:00:00Z